KR102689460B1 - Cd200 돌연변이체 및 그의 용도 - Google Patents

Cd200 돌연변이체 및 그의 용도 Download PDF

Info

Publication number
KR102689460B1
KR102689460B1 KR1020237004504A KR20237004504A KR102689460B1 KR 102689460 B1 KR102689460 B1 KR 102689460B1 KR 1020237004504 A KR1020237004504 A KR 1020237004504A KR 20237004504 A KR20237004504 A KR 20237004504A KR 102689460 B1 KR102689460 B1 KR 102689460B1
Authority
KR
South Korea
Prior art keywords
val
thr
leu
ser
lys
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020237004504A
Other languages
English (en)
Korean (ko)
Other versions
KR20230025937A (ko
Inventor
필립 헉슬리
조셉 쉐리단
조나단 힐
Original Assignee
두센티스 바이오테라퓨틱스 리미티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 두센티스 바이오테라퓨틱스 리미티드 filed Critical 두센티스 바이오테라퓨틱스 리미티드
Publication of KR20230025937A publication Critical patent/KR20230025937A/ko
Application granted granted Critical
Publication of KR102689460B1 publication Critical patent/KR102689460B1/ko
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/1774—Immunoglobulin superfamily (e.g. CD2, CD4, CD8, ICAM molecules, B7 molecules, Fc-receptors, MHC-molecules)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Cell Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Toxicology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
KR1020237004504A 2016-05-10 2017-05-10 Cd200 돌연변이체 및 그의 용도 Active KR102689460B1 (ko)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
GBGB1608197.8A GB201608197D0 (en) 2016-05-10 2016-05-10 Novel proteins
GB1608197.8 2016-05-10
KR1020187035514A KR102498901B1 (ko) 2016-05-10 2017-05-10 Cd200 돌연변이체 및 그의 용도
PCT/GB2017/051303 WO2017194941A1 (en) 2016-05-10 2017-05-10 Cd200 mutant and its uses

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
KR1020187035514A Division KR102498901B1 (ko) 2016-05-10 2017-05-10 Cd200 돌연변이체 및 그의 용도

Publications (2)

Publication Number Publication Date
KR20230025937A KR20230025937A (ko) 2023-02-23
KR102689460B1 true KR102689460B1 (ko) 2024-07-26

Family

ID=56297468

Family Applications (2)

Application Number Title Priority Date Filing Date
KR1020237004504A Active KR102689460B1 (ko) 2016-05-10 2017-05-10 Cd200 돌연변이체 및 그의 용도
KR1020187035514A Active KR102498901B1 (ko) 2016-05-10 2017-05-10 Cd200 돌연변이체 및 그의 용도

Family Applications After (1)

Application Number Title Priority Date Filing Date
KR1020187035514A Active KR102498901B1 (ko) 2016-05-10 2017-05-10 Cd200 돌연변이체 및 그의 용도

Country Status (14)

Country Link
US (1) US11203628B2 (enExample)
EP (1) EP3455247A1 (enExample)
JP (1) JP6997767B2 (enExample)
KR (2) KR102689460B1 (enExample)
CN (1) CN109219614B (enExample)
AU (1) AU2017264825B2 (enExample)
CA (1) CA3023601A1 (enExample)
EA (1) EA201892554A1 (enExample)
GB (1) GB201608197D0 (enExample)
IL (1) IL262846B2 (enExample)
MX (1) MX386295B (enExample)
SG (1) SG11201809677XA (enExample)
WO (1) WO2017194941A1 (enExample)
ZA (1) ZA201807079B (enExample)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201608197D0 (en) 2016-05-10 2016-06-22 Ducentis Biotherapeutics Ltd Novel proteins
KR102186780B1 (ko) 2019-02-18 2020-12-04 박주현 비행부와 탑승부를 분리하여 축으로 결합한 유인드론
CN110859951A (zh) * 2019-09-23 2020-03-06 中国药科大学 Cd200蛋白和cd200融合蛋白在制备治疗银屑病药物中的应用
GB202115803D0 (en) * 2021-11-03 2021-12-15 Ducentis Biotherapeutics Ltd Novel proteins
CA3251037A1 (en) * 2022-05-06 2023-11-09 Ducentis Biotherapeutics Limited NEW CD200 FUSION PROTEINS
AU2023265174A1 (en) * 2022-05-06 2024-12-12 Ducentis Biotherapeutics Limited Novel cd200 fusion proteins
GB2626300A (en) * 2022-12-08 2024-07-24 Ducentis Biotherapeutics Ltd Mutated CD200 proteins and methods of use therof
GB202303291D0 (en) 2023-03-07 2023-04-19 Secr Defence Medicament and medicament combination for use in the treatment of infectious disease
GB202306711D0 (en) * 2023-05-05 2023-06-21 Ducentis Biotherapeutics Ltd Novel proteins
WO2025106841A1 (en) * 2023-11-15 2025-05-22 The University Of Chicago Methods and compositions for inducing antigen specific tolerance

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2001522867A (ja) 1997-11-07 2001-11-20 レジナルド・エム・ゴルツィンスキー 免疫調節のための方法および組成物
JP2004513660A (ja) 2000-11-22 2004-05-13 トリリウム　セラピューティクス　インコーポレーティッド 切断型ｃｄ２００

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7223729B2 (en) * 1997-11-07 2007-05-29 Trillium Therapeutics Inc. Methods of treating allergy by administering a CD200 protein
JP2002541210A (ja) * 1999-04-13 2002-12-03 シェーリング コーポレイション 哺乳動物ｏｘ２タンパク質および関連試薬の新規な使用
AU2001245280A1 (en) * 2000-03-07 2001-09-17 Hyseq, Inc. Novel nucleic acids and polypeptides
JP5364870B2 (ja) * 2005-08-19 2013-12-11 アッヴィ・インコーポレイテッド 二重可変ドメイン免疫グロブリン及びその使用
EP2121015A4 (en) * 2007-01-11 2010-03-24 Boehringer Ingelheim Int CD200 AND RECEPTOR THEREFOR, CD200R AND BONE MASS MODULATION BY ESTEOKLASTENDIFFERENZIERUNG
US8753639B2 (en) * 2009-03-31 2014-06-17 University Of Washington Through Its Center For Commercialization Compositions and methods for modulating the activity of complement regulatory proteins on target cells
JP6012473B2 (ja) * 2010-01-11 2016-10-25 アレクシオン ファーマシューティカルズ， インコーポレイテッド 抗ｃｄ２００抗体を用いたヒトの処置における免疫調節効果のバイオマーカー
GB201608197D0 (en) 2016-05-10 2016-06-22 Ducentis Biotherapeutics Ltd Novel proteins

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2001522867A (ja) 1997-11-07 2001-11-20 レジナルド・エム・ゴルツィンスキー 免疫調節のための方法および組成物
JP2004513660A (ja) 2000-11-22 2004-05-13 トリリウム　セラピューティクス　インコーポレーティッド 切断型ｃｄ２００

Also Published As

Publication number Publication date
IL262846A (en) 2018-12-31
SG11201809677XA (en) 2018-11-29
ZA201807079B (en) 2019-07-31
CA3023601A1 (en) 2017-11-16
KR20190003761A (ko) 2019-01-09
KR20230025937A (ko) 2023-02-23
IL262846B2 (en) 2023-02-01
AU2017264825B2 (en) 2021-04-08
CN109219614B (zh) 2022-05-24
WO2017194941A1 (en) 2017-11-16
IL262846B (en) 2022-10-01
EA201892554A1 (ru) 2019-04-30
US11203628B2 (en) 2021-12-21
MX2018013778A (es) 2019-08-01
JP6997767B2 (ja) 2022-03-04
NZ747665A (en) 2025-10-31
US20190367580A1 (en) 2019-12-05
MX386295B (es) 2025-03-18
CN109219614A (zh) 2019-01-15
BR112018073280A2 (pt) 2019-03-19
KR102498901B1 (ko) 2023-02-10
EP3455247A1 (en) 2019-03-20
JP2019518788A (ja) 2019-07-04
AU2017264825A1 (en) 2018-11-15
GB201608197D0 (en) 2016-06-22

Similar Documents

Publication Publication Date Title
KR102498901B1 (ko) Cd200 돌연변이체 및 그의 용도
JP2018519834A (ja) ヒトＦｃ受容体に結合する融合タンパク質
US20250026805A1 (en) Novel proteins
US20260116946A1 (en) Novel cd200 fusion proteins
CN102470157B (zh) 广谱erbb配体结合分子及其制备和使用方法
EA042608B1 (ru) Мутант cd200 и его применения
US20260116951A1 (en) Novel cd200 fusion proteins
BR112018073280B1 (pt) Proteína cd200 mutada, proteína de fusão compreendendo a mesma, composição farmacêutica e uso das referidas proteínas ou composição para o tratamento de doença autoimune
US12122813B2 (en) Fusion protein comprising an antigen binding domain and a cytokine trimer domain
JP2026516066A (ja) Ｃｄ２００融合タンパク質
KR20260007620A (ko) Cd200 융합 단백질
CA3248283A1 (en) IL-15 AGONISTS FOR TREATING CANCER

Legal Events

Date Code Title Description
A107 Divisional application of patent
PA0104 Divisional application for international application

Comment text: Divisional Application for International Patent

Patent event code: PA01041R01D

Patent event date: 20230207

Application number text: 1020187035514

Filing date: 20181207

PG1501 Laying open of application
E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20231120

Patent event code: PE09021S01D

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

Patent event code: PE07011S01D

Comment text: Decision to Grant Registration

Patent event date: 20240528

GRNT Written decision to grant
PR0701 Registration of establishment

Comment text: Registration of Establishment

Patent event date: 20240724

Patent event code: PR07011E01D

PR1002 Payment of registration fee

Payment date: 20240724

End annual number: 3

Start annual number: 1

PG1601 Publication of registration